Vericel Reports Publication of Results from the Phase 3 SUMMIT Extension Study Demonstrating Sustained Clinical Benefit of MACI Out to Five Years
Vericel Corporation (VCEL)
Last vericel corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vcel.com/investor-relations
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of results from the MACI® (autologous cultured chondrocytes on porcine collagen membrane) Phase 3 SUMMIT Extension Study in the American Journal of Sports Medicine. The results demonstrated that the significantly greater improvements in Knee injury and Osteoarthritis Outcome Score (KOOS)1 pain and function scores for MACI versus microfracture shown in the two-year Phase 3 SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) study were maintained over the additional three-year follow-up in the SUMMIT Extension Study. MACI is an autologous cellular scaffold product indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. MACI is the first FDA-approved product that appl
Show less
Read more
Impact Snapshot
Event Time:
VCEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCEL alerts
High impacting Vericel Corporation news events
Weekly update
A roundup of the hottest topics
VCEL
News
- Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even [Yahoo! Finance]Yahoo! Finance
- Global Cell and Gene Therapy Markets Report 2024-2028 Featuring Main Players - Mallinckrodt, Vericel, Gilead Sciences, Pharmicell, and Bristol-Myers Squibb [Yahoo! Finance]Yahoo! Finance
- Vericel Co. (NASDAQ: VCEL) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $54.00 price target on the stock.MarketBeat
- Treatment Options to Help Overcome Knee Pain for Sports Enthusiasts [Yahoo! Finance]Yahoo! Finance
- US$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results [Yahoo! Finance]Yahoo! Finance
VCEL
Earnings
- 2/29/24 - Beat
VCEL
Analyst Actions
- 1/30/24 - TheStreet
VCEL
Sec Filings
- 4/18/24 - Form 144
- 4/17/24 - Form 144
- 4/11/24 - Form 4
- VCEL's page on the SEC website